Position
Maniro Ltd in Neumora Therapeutics, Inc.
Back to the book · All holders of NMRA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $25.3K$1.79 → $1.95
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 158.2K | $283.2K | — | — | — | 0.1% |
| Q1 2026 | 158.2K | $308.6K | $1.95 | $25.3K | −$0 | 0.1% |